GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » Ending Cash Position

Getein Biotech (SHSE:603387) Ending Cash Position : ¥417 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Getein Biotech Ending Cash Position?

Getein Biotech's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥417 Mil.

Getein Biotech's quarterly Ending Cash Position increased from Sep. 2023 (¥407 Mil) to Dec. 2023 (¥483 Mil) but then declined from Dec. 2023 (¥483 Mil) to Mar. 2024 (¥417 Mil).

Getein Biotech's annual Ending Cash Position declined from Dec. 2021 (¥945 Mil) to Dec. 2022 (¥641 Mil) and declined from Dec. 2022 (¥641 Mil) to Dec. 2023 (¥483 Mil).

Getein Biotech Ending Cash Position Historical Data

The historical data trend for Getein Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getein Biotech Ending Cash Position Chart

Getein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 656.65 797.37 945.15 640.99 483.18

Getein Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 732.98 538.08 407.47 483.18 417.29

Getein Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Getein Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=640.987+-157.811
=483

Getein Biotech's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=483.176+-65.889
=417

Getein Biotech Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Getein Biotech's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Getein Biotech (SHSE:603387) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » Ending Cash Position
Comparable Companies
SHSE:688108 SZSE:002932 SHSE:688085 SZSE:300206 SZSE:300318 SZSE:300143 SHSE:605186 SZSE:300326 SHSE:688581 SZSE:002022 ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Website
http://www.bio-gp.com.cn
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
Executives
Su En Kui Director
Yan Bin Director
Kong Ting Ting Director
Xu Xing De Director
Su En Ben Director

Getein Biotech (SHSE:603387) Headlines

No Headlines